Therapeutic use of anti-TF-Antigen antibody

• US 20060018913A1
• Filed: 07/26/2005
• Published: 01/26/2006
• Est. Priority Date: 07/26/2004
• Status: Active Grant

• Current Assignee: The Research Foundation for The State University of New York (State University of New York)
• Original Assignee: The Research Foundation for The State University of New York (State University of New York)
• Inventors: Rittenhouse-Olson, Kate
• Granted Patent: US 7,374,755 B2
• Time in Patent Office: Days
• US Class Current: 424/178.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/6819 Plant toxins
• CPC Class Codes: A61K 47/6829 Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
• CPC Class Codes: A61K 47/6851 the antibody targeting a determinant of a tumour cell
• CPC Class Codes: A61K 47/6855 the tumour determinant being from breast cancer cell
• CPC Class Codes: A61K 51/1045 against animal or human tumor cells or tumor cell determinants
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF-Ag, or for detection of tumors or metastatic foci which express TF-Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF-Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF-Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metatstatic foci or tumors which comprise cancer cells expressing TF-Ag.

Claims

1. A method for inhibiting in an individual metastasis of cells expressing TF-Ag molecules, comprising administering to the individual an amount of monoclonal antibody JAA-F11 or a fragment thereof sufficient to inhibit the metastasis of the cells expressing the TF-Ag molecules, such that the metastasis of the cells expressing the TF-Ag molecules is inhibited.

2. The method of claim 1, wherein the fragment is selected from the group consisting of Fab, Fab′

, F(ab′

)₂, and Fv.

3. The method of claim 1, wherein the cells expressing the TF-Ag molecules are selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and pancreas cancer cells.

4. The method of claim 1, wherein the monoclonal-antibody JAA-F11 is humanized.

5. The method of claim 1, wherein the monoclonal antibody JAA-F11 is conjugated to an agent selected from the group consisting of toxins and radioactive isotopes.

6. The method of claim 5, wherein the toxin is selected from the group consisting of diphtheria A chain and ricin A chain.

7. The method of claim 5, wherein the radioactive isotope is selected from the group consisting of, I¹²³;

I¹²⁵I¹²⁴ and I¹³¹.

8. The method of claim 1, wherein the monoclonal antibody JAA-F11 is administered simultaneously or sequentially with a chemotherapeutic agent.

9. The method of claim 1, wherein the monoclonal antibody JAA-F11 is administered by a route selected from the group consisting of parenteral, subcutaneous, intraperitoneal, intravenous, intralymphatic and intrapulmonary administration.

20. The method of claim 5, wherein the radioactive isotope is selected from the group consisting of, I¹²³, I¹²⁵ and I¹³¹.

10. A method for identifying metastatic foci or one or more tumors in an individual, wherein the metastatic foci or the one or more tumors comprise cells expressing TF-Ag, comprising the steps of:

a) administering to the individual monoclonal antibody JAA-F11, wherein the monoclonal antibody JAA-F11 has been conjugated to a detectable label; and

b) detecting the detectable label to identify the metatstatic foci or one or more tumors.

11. The method of claim 10, wherein the detectable label is selected from the group consisting of iodine¹²³, iodine¹³¹, iodine¹²⁴, indium¹¹¹ and fluorine¹⁹.

12. The method of claim 10, wherein detecting the detectable label is performed by magnetic resonance imaging or single photon emission computed tomography.

13. The method of claim 10, wherein the one or more tumor or the metastatic foci comprise cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and pancreas cancer cells.

14. A method for inhibiting in an individual the growth of cancer cells expressing TF-Ag, comprising administering to the individual an amount of monoclonal antibody JAA-F11 or a fragment thereof sufficient to inhibit the growth of the cancer cells, such that the growth of the cancer cells is inhibited.

15. The method of claim 14, wherein the fragment is selected from the group consisting of Fab, Fab′

, F(ab′

)₂, and Fv.

16. The method of claim 14, wherein the cells expressing the TF-Ag molecules are selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and pancreas cancer cells.

17. The method of claim 14, wherein the monoclonal antibody JAA-F11 is humanized.

18. The method of claim 14, wherein the monoclonal antibody JAA-F11 is conjugated to an agent selected from the group consisting of toxins and radioactive isotopes.

19. The method of claim 14, wherein the toxin is selected from the group consisting of diphtheria A chain and ricin A chain